TY - JOUR
T1 - Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection
AU - Takata, Hiroshi
AU - Buranapraditkun, Supranee
AU - Kessing, Cari
AU - Fletcher, James L.K.
AU - Muir, Roshell
AU - Tardif, Virginie
AU - Cartwright, Pearline
AU - Vandergeeten, Claire
AU - Bakeman, Wendy
AU - Nichols, Carmen N.
AU - Pinyakorn, Suteeraporn
AU - Hansasuta, Pokrath
AU - Kroon, Eugene
AU - Chalermchai, Thep
AU - O'Connell, Robert
AU - Kim, Jerome
AU - Phanuphak, Nittaya
AU - Robb, Merlin L.
AU - Michael, Nelson L.
AU - Chomont, Nicolas
AU - Haddad, Elias K.
AU - Ananworanich, Jintanat
AU - Trautmann, Lydie
N1 - Publisher Copyright:
© Copyright The Authors 2017, American Association for the Advancement of Science.
PY - 2017/2/15
Y1 - 2017/2/15
N2 - CD8+ T cells play a critical role in controlling HIV viremia and could be important in reducing HIV-infected cells in approaches to eradicate HIV. The simian immunodeficiency virus model provided the proof of concept for a CD8+ T cell-mediated reservoir clearance but showed conflicting evidence on the role of these cells to eliminate HIV-infected cells. In humans, HIV-specific CD8+ T cell responses have not been associated with a reduction of the HIV-infected cell pool in vivo. We studied HIV-specific CD8+ T cells in the RV254 cohort of individuals initiating ART in the earliest stages of acute HIV infection (AHI). We showed that the HIV-specific CD8+ T cells generated as early as AHI stages 1 and 2 before peak viremia are delayed in expanding and acquiring effector functions but are endowed with higher memory potential. In contrast, the fully differentiated HIV-specific CD8+ T cells at peak viremia in AHI stage 3 were more prone to apoptosis but were associated with a steeper viral load decrease after ART initiation. Their capacity to persist in vivo after ART initiation correlated with a lower HIV DNA reservoir. These findings demonstrate that HIV-specific CD8+ T cell magnitude and differentiation are delayed in the earliest stages of infection. These results also demonstrate that potent HIV-specific CD8+ T cells contribute to the reduction of the pool of HIV-producing cells and the HIV reservoir seeding in vivo and provide the rationale to design interventions aiming at inducing these potent responses to cure HIV infection.
AB - CD8+ T cells play a critical role in controlling HIV viremia and could be important in reducing HIV-infected cells in approaches to eradicate HIV. The simian immunodeficiency virus model provided the proof of concept for a CD8+ T cell-mediated reservoir clearance but showed conflicting evidence on the role of these cells to eliminate HIV-infected cells. In humans, HIV-specific CD8+ T cell responses have not been associated with a reduction of the HIV-infected cell pool in vivo. We studied HIV-specific CD8+ T cells in the RV254 cohort of individuals initiating ART in the earliest stages of acute HIV infection (AHI). We showed that the HIV-specific CD8+ T cells generated as early as AHI stages 1 and 2 before peak viremia are delayed in expanding and acquiring effector functions but are endowed with higher memory potential. In contrast, the fully differentiated HIV-specific CD8+ T cells at peak viremia in AHI stage 3 were more prone to apoptosis but were associated with a steeper viral load decrease after ART initiation. Their capacity to persist in vivo after ART initiation correlated with a lower HIV DNA reservoir. These findings demonstrate that HIV-specific CD8+ T cell magnitude and differentiation are delayed in the earliest stages of infection. These results also demonstrate that potent HIV-specific CD8+ T cells contribute to the reduction of the pool of HIV-producing cells and the HIV reservoir seeding in vivo and provide the rationale to design interventions aiming at inducing these potent responses to cure HIV infection.
UR - http://www.scopus.com/inward/record.url?scp=85013399115&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aag1809
DO - 10.1126/scitranslmed.aag1809
M3 - Article
C2 - 28202771
AN - SCOPUS:85013399115
SN - 1946-6234
VL - 9
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 377
M1 - eaag1809
ER -